SI2411408T2 - Topna protitelesa "samo s težko verigo" - Google Patents

Topna protitelesa "samo s težko verigo"

Info

Publication number
SI2411408T2
SI2411408T2 SI201031110T SI201031110T SI2411408T2 SI 2411408 T2 SI2411408 T2 SI 2411408T2 SI 201031110 T SI201031110 T SI 201031110T SI 201031110 T SI201031110 T SI 201031110T SI 2411408 T2 SI2411408 T2 SI 2411408T2
Authority
SI
Slovenia
Prior art keywords
antibodies
soluble
heavy
chain
Prior art date
Application number
SI201031110T
Other languages
English (en)
Other versions
SI2411408T1 (sl
Inventor
Franklin Gerardus Grosveld
Richard Wilhelm Janssens
Dubravka Drabek
Tao Chen
Boer Ernie De
Roger Kingdon Craig
Original Assignee
Erasmus University Medical Center Rotterdam
Roger Kingdon Craig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40640054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2411408(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erasmus University Medical Center Rotterdam, Roger Kingdon Craig filed Critical Erasmus University Medical Center Rotterdam
Publication of SI2411408T1 publication Critical patent/SI2411408T1/sl
Publication of SI2411408T2 publication Critical patent/SI2411408T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SI201031110T 2009-03-24 2010-03-19 Topna protitelesa "samo s težko verigo" SI2411408T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0905023.8A GB0905023D0 (en) 2009-03-24 2009-03-24 Binding molecules
PCT/GB2010/000500 WO2010109165A2 (en) 2009-03-24 2010-03-19 Binding molecules
EP10711069.4A EP2411408B2 (en) 2009-03-24 2010-03-19 Soluble "heavy-chain only" antibodies

Publications (2)

Publication Number Publication Date
SI2411408T1 SI2411408T1 (sl) 2016-03-31
SI2411408T2 true SI2411408T2 (sl) 2023-06-30

Family

ID=40640054

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031110T SI2411408T2 (sl) 2009-03-24 2010-03-19 Topna protitelesa "samo s težko verigo"

Country Status (24)

Country Link
US (2) US8883150B2 (sl)
EP (1) EP2411408B2 (sl)
JP (1) JP5836927B2 (sl)
KR (1) KR20120068757A (sl)
CN (1) CN102482342B (sl)
BR (1) BRPI1012694A2 (sl)
CA (1) CA2756171C (sl)
CY (1) CY1117203T1 (sl)
DK (1) DK2411408T4 (sl)
ES (1) ES2563321T5 (sl)
FI (1) FI2411408T4 (sl)
GB (1) GB0905023D0 (sl)
HR (1) HRP20160158T4 (sl)
HU (1) HUE026473T2 (sl)
MX (1) MX2011010027A (sl)
PL (1) PL2411408T5 (sl)
PT (1) PT2411408E (sl)
RU (1) RU2528737C2 (sl)
SG (1) SG174510A1 (sl)
SI (1) SI2411408T2 (sl)
SM (1) SMT201600044B (sl)
TW (1) TW201040264A (sl)
WO (1) WO2010109165A2 (sl)
ZA (1) ZA201106983B (sl)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311874B1 (en) 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
AU2007219159B8 (en) * 2006-01-25 2012-06-28 Roger Kingdon Craig Generation of heavy-chain only antibodies in transgenic animals
KR101826224B1 (ko) 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
CA2747534C (en) 2008-12-18 2020-08-18 Erasmus University Medical Center Rotterdam Non-human transgenic animals expressing humanised antibodies and use therof
DK2564695T3 (en) 2009-07-08 2015-05-26 Kymab Ltd Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
EP3248462B1 (en) 2010-03-31 2024-03-13 Ablexis, LLC Genetic engineering of mice for the production of chimeric antibodies
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
WO2012104227A1 (en) * 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
CN107056936B (zh) 2011-09-19 2021-09-03 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201913164YA (en) 2011-12-20 2020-03-30 Regeneron Pharma Humanized light chain mice
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
CA2876172C (en) * 2012-06-12 2021-01-19 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
JP5993102B2 (ja) 2013-02-20 2016-09-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 修飾された免疫グロブリン重鎖配列を有する非ヒト動物
EP2967012B1 (en) 2013-03-14 2020-09-16 Erasmus University Medical Center Rotterdam Transgenic non-human mammal for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US10119134B2 (en) 2013-03-15 2018-11-06 Abvitro Llc Single cell bar-coding for antibody discovery
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
EP3051942B1 (en) 2013-10-01 2020-09-02 Kymab Limited Animal models and therapeutic molecules
JP2017512831A (ja) * 2014-03-20 2017-05-25 大塚製薬株式会社 置換フェニル−（１，３−ジヒドロ−イソインドール−２−イル）−メタノンを含んでなる医薬処方物
JP2017510273A (ja) 2014-03-21 2017-04-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 異なる結合特性を示すｖｌ抗原結合タンパク質
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
ES2727656T3 (es) 2014-09-15 2019-10-17 Abvitro Llc Secuenciación de alto rendimiento de banco de nucleótidos
EP3209699A1 (en) * 2014-10-22 2017-08-30 Crescendo Biologics Limited Vh scaffold
EP3209776A1 (en) * 2014-10-22 2017-08-30 Crescendo Biologics Limited Human vh domain scaffolds
CN104710528B (zh) * 2015-03-13 2019-02-15 西北农林科技大学 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用
AU2016232715A1 (en) 2015-03-19 2017-09-28 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016150845A1 (en) * 2015-03-20 2016-09-29 Ablynx Nv Glycosylated immunoglobulin single variable domains
US20180094243A1 (en) * 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2017020001A2 (en) 2015-07-29 2017-02-02 Allergan, Inc. Heavy chain only antibodies to ang-2
CA2992788A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
CN105777894A (zh) * 2016-03-12 2016-07-20 长春力太生物技术有限公司 通过转基因啮齿类动物制备人源化驼类单域抗体的方法
EP3440194A1 (en) 2016-04-04 2019-02-13 ETH Zurich Mammalian cell line for protein production and library generation
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
EP3503722A1 (en) 2016-08-24 2019-07-03 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
IL265321B2 (en) 2016-09-14 2024-01-01 Teneobio Inc CD3 binding antibodies
US10968281B2 (en) * 2016-10-14 2021-04-06 Institut Curie Anti-LSP1 antibody
CN109906030B (zh) * 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
JP7254699B2 (ja) * 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
US11267904B2 (en) * 2016-12-28 2022-03-08 Sysmex Corporation Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
KR20190104400A (ko) * 2017-01-19 2019-09-09 오픈 모노클로날 테크놀로지, 인코포레이티드 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
CN117567624A (zh) * 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
SG11201912774RA (en) * 2017-06-20 2020-01-30 Teneobio Inc Anti-bcma heavy chain-only antibodies
MX2020002802A (es) 2017-09-13 2020-10-12 Teneobio Inc Anticuerpos de cadena pesada que se unen a ectoenzimas.
PL3710484T3 (pl) * 2017-12-20 2024-03-25 Harbour Biomed (Shanghai) Co., Ltd Przeciwciała wiążące ctla-4 i ich zastosowania
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
US11905327B2 (en) 2017-12-28 2024-02-20 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
AU2019237926A1 (en) * 2018-03-21 2020-09-24 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
SG11202006674QA (en) 2018-03-30 2020-08-28 Nanjing Legend Biotech Co Ltd Single-domain antibodies against lag-3 and uses thereof
WO2019241002A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Transgenic chicken that makes antibodies with long cdr-h3s stabilized by multiple disulfide bridges and diversified by gene conversion
KR20210021024A (ko) * 2018-06-13 2021-02-24 크리스탈 바이오사이언스 주식회사 유전자 변환에 의한 자율 중쇄 가변 도메인의 수정에 의한 항체 생산
AU2019305663A1 (en) 2018-07-20 2021-03-11 TeneoTwo, Inc Heavy chain antibodies binding to cd19
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
KR20210086651A (ko) 2018-10-26 2021-07-08 테네오바이오, 인코포레이티드 Cd38에 결합하는 중쇄 항체
CN113874394B (zh) 2019-02-20 2024-01-19 和铂抗体有限公司 抗体
SG11202111027WA (en) 2019-04-05 2021-11-29 Teneobio Inc Heavy chain antibodies binding to psma
MX2021015045A (es) 2019-06-07 2022-03-17 Amgen Inc Construcciones de unión biespecíficas.
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
CA3158579A1 (en) 2019-12-18 2021-06-24 Pranjali DALVI Heavy chain antibodies binding to cd38
GB202003632D0 (en) 2020-03-12 2020-04-29 Harbour Antibodies Bv SARS-Cov-2 (SARS2, COVID-19) antibodies
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
TWI806088B (zh) 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 具有H2L2與HCAb結構的結合蛋白
JP2023530766A (ja) 2020-06-30 2023-07-19 ハーバー・バイオメド・ユーエス・インコーポレイテッド 二重特異性抗体及びその用途
US20230257473A1 (en) 2020-06-30 2023-08-17 Teneobio, Inc. Multi-specific antibodies binding to bcma
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
GB202017555D0 (en) 2020-11-06 2020-12-23 Harbour Antibodies Bv Antibody-conjugated nanoparticles
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CA3203468A1 (en) 2020-12-03 2022-06-09 Amgen Inc. Immunoglobuline constructs with multiple binding domains
US20240050583A1 (en) 2020-12-08 2024-02-15 Harbour Biomed (Shanghai) Co., Ltd Protein-drug conjugate and site-specific conjugating method
EP4258865A1 (en) * 2020-12-09 2023-10-18 Trianni, Inc. Heavy chain-only antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
CN117500835A (zh) 2021-02-25 2024-02-02 特尼奥生物股份有限公司 抗psma抗体及car-t结构
KR20230150825A (ko) 2021-02-26 2023-10-31 테네오바이오, 인코포레이티드 항-muc1-c 항체 및 car-t 구조
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
BR112023020450A2 (pt) 2021-04-06 2024-01-23 Teneobio Inc Anticorpos anti-cd19 e estruturas car-t
EP4323403A1 (en) 2021-04-16 2024-02-21 Teneobio, Inc. Anti-cd20 antibodies and car-t structures
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
GB202112935D0 (en) 2021-09-10 2021-10-27 Harbour Antibodies Bv Sars-cov-2 (sars2, covid-19) heavy chain only antibodies
WO2023036982A1 (en) 2021-09-10 2023-03-16 Harbour Antibodies Bv Anti-sars2-s antibodies
WO2023246578A1 (zh) * 2022-06-24 2023-12-28 成都科伦精准生物科技有限公司 特异性结合gpc3的嵌合抗原受体及其应用
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333941A1 (de) 1983-09-20 1985-04-04 Karl Kässbohrer Fahrzeugwerke GmbH, 7900 Ulm Fraese
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
ATE461282T1 (de) 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20030022240A1 (en) * 2001-04-17 2003-01-30 Peizhi Luo Generation and affinity maturation of antibody library in silico
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
CN100497389C (zh) 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
EP1597280B2 (en) * 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
EP2311874B1 (en) * 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
AU2005325801A1 (en) * 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
RU2433139C2 (ru) * 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
DE202005011297U1 (de) 2005-07-18 2005-11-03 Trw Automotive Electronics & Components Gmbh & Co. Kg Fahrzeug-Haltegriff
AU2007219159B8 (en) 2006-01-25 2012-06-28 Roger Kingdon Craig Generation of heavy-chain only antibodies in transgenic animals
GB0618345D0 (en) 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US7731969B1 (en) * 2006-12-06 2010-06-08 Neoclone Biotechnology International, Llc Methods for developing and producing antigen-specific antibody-producing cells
DK2336329T3 (da) 2007-06-01 2013-01-07 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunglobulingener og til produktion af transgene, humane, idiotypiske antistoffer
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2008295248A1 (en) 2007-09-07 2009-03-12 Symphogen A/S Methods for recombinant manufacturing of anti-RSV antibodies
MY172472A (en) 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
JP6282000B6 (ja) 2015-06-22 2018-06-27 株式会社日立国際電気 電力増幅装置

Also Published As

Publication number Publication date
PL2411408T3 (pl) 2016-05-31
JP2012521211A (ja) 2012-09-13
HUE026473T2 (en) 2016-06-28
MX2011010027A (es) 2011-12-14
US20120151610A1 (en) 2012-06-14
CA2756171A1 (en) 2010-09-30
WO2010109165A8 (en) 2011-10-20
FI2411408T4 (fi) 2023-05-08
SG174510A1 (en) 2011-10-28
SMT201600044B (it) 2016-02-25
EP2411408A2 (en) 2012-02-01
US8883150B2 (en) 2014-11-11
HRP20160158T4 (hr) 2023-04-28
ES2563321T5 (es) 2023-06-26
PL2411408T5 (pl) 2023-07-10
AU2010227291A1 (en) 2011-10-27
US9365655B2 (en) 2016-06-14
HRP20160158T1 (hr) 2016-03-11
TW201040264A (en) 2010-11-16
EP2411408B2 (en) 2023-03-22
RU2528737C2 (ru) 2014-09-20
RU2011142759A (ru) 2013-04-27
EP2411408B1 (en) 2015-11-25
GB0905023D0 (en) 2009-05-06
CY1117203T1 (el) 2017-04-05
DK2411408T3 (en) 2016-01-11
CN102482342A (zh) 2012-05-30
ES2563321T3 (es) 2016-03-14
BRPI1012694A2 (pt) 2018-01-16
PT2411408E (pt) 2016-03-03
ZA201106983B (en) 2014-12-23
DK2411408T4 (da) 2023-04-24
US20130323235A1 (en) 2013-12-05
AU2010227291A8 (en) 2011-11-17
CA2756171C (en) 2020-04-28
JP5836927B2 (ja) 2015-12-24
WO2010109165A2 (en) 2010-09-30
WO2010109165A3 (en) 2011-02-24
CN102482342B (zh) 2014-11-12
KR20120068757A (ko) 2012-06-27
SI2411408T1 (sl) 2016-03-31

Similar Documents

Publication Publication Date Title
ZA201106983B (en) Soluble "heavy-chain only" antibodies
IL214996A0 (en) Anti-bcma antibodies
IL218724A0 (en) Endoglin antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
GB0708002D0 (en) Antibodies
PT3023438T (pt) Anticorpos anti-gitr
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
ZA201104545B (en) Anti-siglec-15 antibody
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
GB0821100D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0920324D0 (en) Antibodies
HK1170745A1 (en) Antibodies against il-17br il-17br
ZA201007976B (en) Anti-pirb antibodies
EP2400984A4 (en) HER2 ANTIBODY COMPOSITIONS
GB0818356D0 (en) Antibodies
GB2473934B (en) Anti-VEEV antibody
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
EP2424892A4 (en) DC-STAMP ANTIBODY
GB0908945D0 (en) Antibodies
GB0724185D0 (en) Antibodies